Sofia M. Efimochkina

Sofia M. Efimochkina

Auto-generated profile, based on publicly available information

Sofia M. Efimochkina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DPDmitry Petelin
Dmitry Petelin
OSO. Yu. Sorokina
O. Yu. Sorokina
DTD. V. Troshina
D. V. Troshina
YSYu. A. Siginevich
Yu. A. Siginevich
SES. M. Efimochkina
S. M. Efimochkina
Beatrice VolelBeatrice Volel
Beatrice Volel
Anxiety disorders are widespread in the population and in general medical practice and have a pronounced negative impact on the quality of life and functioning of patients. Currently, the prerequisites for the diagnosis and treatment of anxiety disorders outside the psychiatric network are accumulating by therapists, general practitioners and other non-psychiatric doctors. A review of the most significant factors contributing to a wider diagnosis and treatment of anxiety disorders in general medical practice is given. This review presents modern ideas about the pathogenesis of anxiety disorders, substantiates the modern idea of their multifactorial nature, the contribution of genetic and epigenetic, psychological and social factors, outlines the concepts of the neurobiological basis of pathological anxiety based on neuroimaging studies. In the future, information is provided on the general manifestations of anxiety disorders, the main clusters of anxiety, the systematics of anxiety disorders according to ICD-10. Modern ideas about the diagnosis of anxiety disorders using both scales and a clinical approach are given, a detailed review of currently available diagnostic scales validated for clinical practice is presented. The main approaches to conducting a clinical conversation are also presented, recommendations are given for the most successful collection of information about the clinical condition of patients. At the end of the review, information is given on existing approaches to psychopharmacotherapy and psychotherapy of anxiety disorders. Taking into account pharmacological and clinical studies, the place of drugs tofisopam (an atypical allosteric modulator of GABA receptors) and buspirone (a partial agonist of serotonin 1A receptors) in the treatment of anxiety disorders in general medical practice has been argued.

1 July 2024 in Russian Journal of Telemedicine and E-Health
Verified
Journal Article
Open access
EBEkaterina Bril
Ekaterina Bril
ASA.I. Shaderkina
A.I. Shaderkina
SES.M. Efimochkina
S.M. Efimochkina
ALAleksandr Litavrin
Aleksandr Litavrin
MKMaria Andreevna Kuznetsova
Maria Andreevna Kuznetsova
RMRussia Moscow
Russia Moscow
Introduction. Neuroimplants are devices that interact with the nervous system for recording, stimulating or replacing neural activity. Neuroimplants refer to invasive technologies and are a particular example of brain-computer interfaces that measure brain activity and interpret it to control external devices and computers. This paper will discuss invasive neurointerfaces (IN), their applications, directions of development and limitations of these technologies. Materials and methods. The search was conducted in PubMed, Google Scholar and Scopus databases, as well as in open Internet sources. Results and discussion. This section presents a description of the most common neuroinvasive structures, their applications in neurology, psychiatry, and fundamental research. In neurology neuroinvasive devices are the most widely spread. They significantly increase the effectiveness of treatment of patients with pharmacoresistant forms of migraine and epilepsy, provide rehabilitation of patients after a stroke and allow them to adapt to the performance of everyday tasks. In psychiatry, neuroimplants are used in the form of DBS (deep brain stimulation) devices that reduce the severity of symptoms of mental disorders by acting on functional networks. Conclusion. Neuroimplants provide opportunities for the treatment of pharmacoresistant diseases, such as pharmacoresistant epilepsy, increasing the quality of life of the patients. Current research interest is focused on developing bidirectional signal devices that, by reading brain activity patterns, analyze them and convert them into signals that allow patients to interact with the outside world.

22 May 2024 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
VSV. A. Sedelkova
V. A. Sedelkova
YTYuliya Tikhonova
Yuliya Tikhonova
MKMarina Kinkulkina
Marina Kinkulkina
SES. M. Efimochkina
S. M. Efimochkina
MKM. D. Khloponina
M. D. Khloponina
YGYu. S. Gotko
Yu. S. Gotko
Based on the results of large-scale genomic studies, the psychotic continuum hypothesis suggests considering disorders characterized by primary psychotic symptoms as part of a single spectrum of neurodevelopmental disorders and implies the existence of a gradient of severity between affective disorders and schizophrenia, with increasing severity of psychotic epsodes and deficits. The continuum hypothesis explains the existence of the previously controversial diagnosis of schizoaffectivedisorder (SAD), which combines clinical manifestations of both schizophrenia and bipolar affective disorder: according to this hypothesis, schizoaffective disorder is assigned an intermediate position in the continuum. The common leading clinical criteria and genetic commonality on the one hand, and the absence of objective disease markers on the other significantly complicate the diagnostic search between the disorders with affective and psychotic symptoms, raising questions not only about their nosological relationships but also about the problem of finding methods of differentiation at early stages of disorder development. Promising tools for differential diagnosis include multifactorial analysis of parameters (genetic, clinical, and socio-demographic parameters, level of social functioning, response to prescribed psychopharmacotherapy), molecular phenotyping of profiles, and the search for laboratory, neuroimaging, and neurobiological markers of diseases. As of today, the main reliable approach in the differential diagnosis of these disorders remains the follow-up approach. The article presents a clinical case describing a 19‑year follow-up of a patient with clinically heterogeneous episodes of affective-delusional symptomatology combined with alcoholism and demonstrating the difficulty of diagnosing disorders with affective and psychotic manifestations, as well as the need for further research in this area.

28 May 2025 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
SFSechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
VSV. A. Sedelkova
V. A. Sedelkova
YTYuliya Tikhonova
Yuliya Tikhonova
SES. M. Efimochkina
S. M. Efimochkina
AAA. V. Anokhina
A. V. Anokhina
MKMarina Kinkulkina
Marina Kinkulkina
Schizophrenia and schizophrenia spectrum disorders (SSD) are characterized by significant cognitive deficits and impairments in social adaptation, which have a profound impact on patients’ quality of life. The present study focuses on the investigation of cognitive impairments and the level of functioning in patients during the remission phase. The study included 93 patients with a confirmed diagnosis of schizophrenia spectrum disorders who underwent clinical and psychometric assessment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), and the UCSD Performance-Based Skills Assessment (UPSA) upon achieving remission. The findings indicate that patients with recurrent psychotic episodes exhibit more pronounced cognitive impairments (particularly in working memory and processing speed) and reduced functional capacity compared to those who experienced a first-episode psychosis. Correlation analysis revealed a strong association between cognitive performance and social functioning. These results highlight the importance of early identification and treatment of cognitive deficits to improve functional outcomes and promote social reintegration. The study’s findings may inform the development of personalized treatment and rehabilitation strategies for individuals with schizophrenia spectrum disorders.

26 June 2026 in Consortium Psychiatricum
Verified
Journal Article
Open access
PDF file
SESofia M. Efimochkina
Sofia M. Efimochkina
VSValentina A. Sedelkova
Valentina A. Sedelkova
YGYulia S. Gotko
Yulia S. Gotko
MKMaria D. Khloponina
Maria D. Khloponina
EKElizaveta S. Kobets
Elizaveta S. Kobets
MKMarina Kinkulkina
Marina Kinkulkina
BACKGROUND: Remote monitoring of remission status in patients with schizophrenia spectrum disorders (SSDs) is a promising approach for the early detection of mental disorder relapses. However, there are currently no validated digital tools available for this purpose in Russia. An important prerequisite for the development of such tools is assessing user experience, as it largely determines patient adherence to self-monitoring. AIM: To evaluate the user experience associated with chatbot-based remote monitoring of remission in patients with schizophrenia spectrum disorders. METHODS: Over a 9-day period, patients completed a digital diary using a chatbot (a total of five morning and five evening sessions). To reduce respondent burden, the diary questions were divided into two blocks. The morning session included a questionnaire for the self-assessment of psychotic and affective symptoms, including 12 items from the Positive and Negative Syndrome Scale (PANSS), 2 items from the Calgary Depression Scale for Schizophrenia (CDSS), the Spiegel Sleep Questionnaire (SSQ), and the 4-item Morisky–Green–Levine Medication Adherence Questionnaire (MGL-4). The evening session included the short-form of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) and the patient version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). After the self-monitoring period had been completed, participants evaluated their experience interacting with the technology using a 21-item questionnaire. RESULTS: The study included 15 patients with SSDs. Most participants (80%) completed more than half of the diary sessions. Participants reported high satisfaction with the chatbot functionality and good acceptability of the technology overall. Among the limitations of the remote monitoring system, participants mentioned the large number of questions and the lack of personalized notifications. CONCLUSION: Patients with SSDs responded positively to the use of a chatbot for remote monitoring of remission. Further improvements should include streamlined patient interactions and personalized features such as medication reminders and visual symptom tracking.

27 June 2024 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
VSV.A. Sedelkova
V.A. Sedelkova
YTYuliya Tikhonova
Yuliya Tikhonova
MKMarina Kinkulkina
Marina Kinkulkina
SES.M. Efimochkina
S.M. Efimochkina
KHKhloponina
Khloponina
YGYu.S. Gotko
Yu.S. Gotko
Based on the results of large-scale genomic studies, the psychotic continuum hypothesis suggests considering disorders characterized by primary psychotic symptoms as part of a single spectrum of neurodevelopmental disorders and implies the existence of a gradient of severity between affective disorders and schizophrenia, with increasing severity of psychotic episodes and deficits. The continuum hypothesis explains the existence of the previously controversial diagnosis of schizoaffective disorder (SAD), which combines clinical manifestations of both schizophrenia and bipolar affective disorder: according to this hypothesis, schizoaffective disorder is assigned an intermediate position in the continuum. The common leading clinical criteria and genetic commonality on the one hand, and the absence of objective disease markers on the other significantly complicate the diagnostic search between the disorders with affective and psychotic symptoms, raising questions not only about their nosological relationships but also about the problem of finding methods of differentiation at early stages of disorder development. Promising tools for differential diagnosis include multifactorial analysis of parameters (genetic, clinical, and socio-demographic parameters, level of social functioning, response to prescribed psychopharmacotherapy), molecular phenotyping of profiles, and the search for laboratory, neuroimaging, and neurobiological markers of diseases. As of today, the main reliable approach in the differential diagnosis of these disorders remains the follow-up approach. The article presents a clinical case describing a 19-year follow-up of a patient with clinically heterogeneous episodes of affective-delusional symptomatology combined with alcoholism and demonstrating the difficulty of diagnosing disorders with affective and psychotic manifestations, as well as the need for further research in this area.